Fund+ in the news
June 21, 2024

Tubulis Doses First Patient in Phase I/IIa Trial Investigating ADC Candidate TUB-040 in Ovarian Cancer and Lung Adenocarcinoma

TUB-040 is a next-generation NaPi2b-targeting Exatecan ADC based on Tubulis’ proprietary P5 technology with superior biophysical properties that demonstrated effective and durable responses in a range of preclinical models The clinical trial will enroll up to 140 patients with platinum-resistant high-grade ovarian cancer or relapsed/refractory adenocarcinoma non-small cell lung cancer in the US, the UK […]

Read Post
April 9, 2024

Novo Nordisk to acquire Cardior Pharmaceuticals and strengthen pipeline in cardiovascular disease

Bagsværd, Denmark, and Hannover, Germany, 25 March, 2024 – Novo Nordisk and Cardior Pharmaceuticals today announced that Novo Nordisk has agreed to acquire Cardior for up to 1.025 billion Euros, including an upfront payment and additional payments if certain development and commercial milestones are achieved. Cardior is a leader in the discovery and development of […]

Read Post
March 14, 2024

Fund+ Portfolio Company Tubulis Closes Upsized EUR 128 Million Series B2 to Accelerate Clinical Development of Solid Tumor-Focused ADC Pipeline

Financing round co-led by EQT Life Sciences and Nextech Invest1, with participation from current and new leading global biotechnology investors Proceeds will support clinical evaluation of lead solid tumor ADC candidates, TUB-030 and TUB-040, further technology development and expansion into the US   MUNICH, GERMANY, March 14, 2024 – Tubulis, a Fund+ portfolio company, today […]

Read Post
August 30, 2023

Confo Therapeutics Appoints Dieter Weinand, Former CEO of Bayer Pharmaceuticals, as Independent Chairman

Ghent, Belgium – August 29, 2023 – Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced the appointment of Dieter Weinand as Independent Chairman of its Board of Directors. Mr. Weinand brings with him a wealth of experience with more than 35 years in the pharmaceutical industry and […]

Read Post
June 15, 2023

Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera

• Collaboration to make use of Confo’s unique suite of ConfoBody®-enabled antibody discovery technologies on two GPCR targets • Confo to receive upfront and milestone payments • Tiered royalties payable to Confo on net sales from resulting products Ghent, Belgium – June 15, 2023 – Confo Therapeutics, a leader in the discovery of medicines targeting […]

Read Post
June 5, 2023

Minoryx gains FDA approval to initiate a Phase 3 clinical trial in patients with cerebral Adrenoleukodystrophy

US trial with leriglitazone to commence in mid-2023 providing an FDA-approved route to US market whilst EMA evaluates European Marketing Authorization Application (MAA) Mataró, Barcelona, Spain, May 31, 2023 – Minoryx Therapeutics, a registration stage biotech company focused on the development of therapies for orphan central nervous system (CNS) disorders, today announces the US Food […]

Read Post
June 5, 2023

Coave Therapeutics announces Positive 12-months Data from Ongoing Phase I/II Clinical Trial of CTx-PDE6b in Patients with Retinitis Pigmentosa Caused by Bi-allelic Mutations in PDE6b

– CTx-PDE6b demonstrated clinically meaningful benefit in visual functions at the highest dose and exhibits a good safety profile – Positive results from the study to date support preparations for a registrational trial for CTx-PDE6b in PDE6b Retinitis Pigmentosa – Regulatory approval received to expand the current study to include younger patients with earlier stages […]

Read Post
June 5, 2023

ONA Therapeutics Announces the Appointment of Dr Pamela Klein to its Board of Directors

• Leading medical oncologist and seasoned biotechnology executive with significant experience in drug development Barcelona, Spain, 23 May 2023: ONA Therapeutics (“ONA”), which is specialized in unravelling novel biology to design biopharmaceuticals attacking advanced cancer, is pleased to announce the appointment of Dr. Pamela Klein as independent member to its board of directors. Dr. Pamela […]

Read Post
May 15, 2023

Indigo Appoints Dr. Arun Venkatasubramanian as Chief Technology Officer

Arun is an award-winning engineer who brings over 15 years’ experience in leading the design and development of transformational technology within the medical, consumer, and military sectors BELGIUM – Ghent, 15 May 2023 – Indigo Diabetes N.V. (‘Indigo’ or the ‘Company’), a pioneering developer of a Continuous Metabolite Monitoring (CMM™) device for people living with […]

Read Post
April 25, 2023

Minoryx presents positive interim results from NEXUS registration study for leriglitazone targeting pediatric ALD patients with cerebral adrenoleukodystrophy (cALD)

Initial evidence of disease stabilization was demonstrated for all patients using radiological, clinical and plasma biomarker assessments at 6 months (24 weeks) of treatment Mataró, Barcelona, Spain, April 25, 2023 – Minoryx Therapeutics, a registration stage biotech company focused on the development of therapies for orphan central nervous system (CNS) disorders, today announces 24-week interim […]

Read Post
April 20, 2023

Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients

Companies join forces bringing together Bristol Myers Squibb’s (BMS) deep oncology and clinical development expertise and Tubulis’ differentiated and unique approach to Antibody-Drug- Conjugate (ADC) design with the goal of delivering the true therapeutic potential of ADCs Tubulis to receive upfront payment of $22.75 million and milestone payments potentially totaling over $1 billion plus tiered […]

Read Post
March 30, 2023

Confo Therapeutics Enters into Collaboration Agreement with Daiichi Sankyo to Discover Novel Medicines for CNS Diseases

Collaboration to make use of Confo’s unique suite of ConfoBody®-enabled technologies for fragment- and structure-based drug design Confo to receive upfront and milestone payments totaling EUR 168M Tiered royalties payable to Confo on net sales from resulting products Ghent, Belgium – March 30, 2023 – Confo Therapeutics, a leader in the discovery of medicines targeting […]

Read Post
March 13, 2023

ExeVir Bio and VIB Announce Data on a New Therapy for Prevention and Treatment for COVID-19.

ExeVir Bio and VIB-UGent’s bioRxiv pre-print reports on S2-binding camelid single-domain antibody-based drug, XVR013, that targets the Achilles’ heel in the SARS-CoV-2 viral spike Focus on protecting the millions of immuno-compromised patients, who are most vulnerable to COVID-19  Ghent, Belgium, 13 March 2023: ExeVir Bio, a biotech company developing robust single domain antibody therapies for broad […]

Read Post
March 2, 2023

Confo Therapeutics Announces Global Licensing Agreement with Lilly for Peripheral Pain Candidate, CFTX-1554

Confo to receive upfront and milestone payments totaling $630M Company is eligible for up to $590M in additional milestones if Lilly proceeds with a second product candidate  Tiered royalties payable to Confo on net sales Confo to have a co-investment option Ghent, Belgium – March 2, 2023 – Confo Therapeutics, a leader in the discovery […]

Read Post
January 30, 2023

Cellaion SA announces a total fundraising of EUR 23 million in 2022 for its phase IIB study in Acute on Chronic Liver Failure with Truffle Capital as lead investor in the final Closing followed by Newton Biocapital, Wallonie Entreprendre and individual investors.

Mont-Saint-Guibert, Belgium, 2023/01/13. Cellaïon is a biotechnology company based in Mont-St-Guibert, active in the field of cell therapy, an area of excellence in the life sciences industry in Wallonia. Its flagship product HepaStem®, in advanced clinical development, targets severe liver diseases, and in particular Acute on Chronic Liver Failure (ACLF). ACLF is an acute hepatic […]

Read Post
January 19, 2023

TargED Biopharmaceuticals announces the appointment of Erik van den Berg as Chair of its Supervisory Board

Utrecht, the Netherlands, January 19, 2023. TargED Biopharmaceuticals, a biotech spin-off of the University Medical Center Utrecht, announced today the appointment of Erik van den Berg as Chair and independent Board Member of its Supervisory Board. Erik holds a Master’s degree in Chemistry from the University of Utrecht, the Netherlands, and a MBA from Manchester […]

Read Post
January 9, 2023

Belgium: ExeVir lands European venture debt financing to develop novel nanobody COVID-19 therapy

ExeVir signs €25 million venture debt financing with European Investment Bank to develop a llama-derived nanobody COVID-19 therapeutic, labelled XVR012. Project expected to have important public health impact, addressing underserved therapeutics market for immunocompromised and elderly people. Venture debt financing is part of EIB’s COVID-19 response and is guaranteed by the InnovFin programme under the EU’s […]

Read Post
December 27, 2022

Novadip Biosciences SA Appoints Judy Ashworth, MD, as Chief Medical Officer

Mont Saint-Guibert, Belgium – December 27, 2022 – Novadip Biosciences SA (“Novadip” or “the Company”), a clinical stage company developing treatments to regenerate impaired tissue in patients with significant unmet medical needs, today announced the appointment of Judy Ashworth, MD, as Chief Medical Officer of the Company. Dr. Ashworth brings deep experience and strong managerial […]

Read Post
December 9, 2022

Novadip Biosciences SA Announces Positive Results from Phase 1/2 Clinical Trial in Patients with Severe Bone Non-Union of the Lower Limb Following Trauma

Study results demonstrate NVD-003 has a favorable safety profile and convincing efficacy including rapid, durable bone healing in patients following failure of conventional treatment  Clinical data will inform development of the Company’s autologous and allogeneic therapeutics for critical size bone defects and common orthopedic conditions First patient enrolled in Phase 1b/2a US/EU clinical trial in […]

Read Post
November 10, 2022

Minoryx and Neuraxpharm announce a strategic alliance to provide a new therapy for rare CNS disease patients in Europe9

The companies enter into a license agreement for the European rights to leriglitazone, currently under EMA review for the orphan indication X-linked Adrenoleukodystrophy (X-ALD) Mataró, Barcelona (Spain) and Düsseldorf (Germany), November 10, 2022 – Minoryx Therapeutics, a late-stage biotech company focused on the development of treatments for orphan central nervous system (CNS) disorders and the […]

Read Post
November 4, 2022

Novadip Biosciences Raises Additional EUR 40 Million Bringing Total Company Funding to EUR 88 Million

Funding will support development of next generation orthopedic products that provide accelerated healing through single treatment cures Equity Funding led by CR-CP Life Science Fund, New Science Ventures, Fund+ and SRIW MONT SAINT-GUIBERT, BELGIUM – November 3, 2022 – Novadip Biosciences (“Novadip” or “the Company”), a clinical-stage biopharmaceutical company developing a new class of regenerative […]

Read Post
October 20, 2022

Coave Therapeutics Strengthens Board of Directors

Paris, France, October 20th, 2022 – Coave Therapeutics (‘Coave’), a biotech company leading the transition of genetic medicine from (ultra) rare to prevalent conditions in neurodegenerative diseases, today announces Frederic Chereau as Chairman of the Board and the appointment of Dr Claudia Mitchell, PhD, MBA to the Company’s Board of Directors as an independent non-executive […]

Read Post
October 20, 2022

ExeVir Bio Forges Ahead with Unique Next Generation COVID-19 Therapy and Appoints Dr. Jeanne Bolger as Chair of the Board of Directors

Targeting final lead therapy selection, neutralizing all known previous and current SARS-CoV2 variants of concern by end 2022 Triple mode of action dengue fever program identified for development Industry veteran with exceptional leadership experience to support ExeVir’s new progressive pipeline against infectious diseases  Ghent, Belgium, 20 Oct 2022: ExeVir is developing robust therapies providing broad protection […]

Read Post
September 30, 2022

Indigo Diabetes Announces First Participant Enrolled in the SHINE Clinical Trial

BELGIUM – Ghent, September 29, 2022 – Indigo Diabetes N.V. (‘Indigo’ or the ‘Company’), a pioneering developer of medical solutions using nanophotonics, today announces the enrollment of the first participant in Belgium in the SHINE clinical trial, which is designed to evaluate the longer-term stability of Indigo’s continuous multi-metabolite (‘CMM’) device. Indigo’s subcutaneously inserted CMM […]

Read Post
September 26, 2022

AstriVax, an innovative vaccine platform company, establishes scientific advisory board with world renowned leaders in vaccine development

• Emmanuel Hanon, PhD, will chair the company’s scientific advisory board. • Professor Peter Piot {MD, PhD) and Professor Patrick Soentjens {MD, PhD) have been appointed as advisors. • Together, they bring complementary expertise in infectious diseases, vaccines, and global health management as well as over 80 years of combined experience. Leuven, Belgium, 24 March […]

Read Post